Impaired glucocorticoid receptor expression and mitochondrial metabolism in MDSCs contribute to glucocorticoid resistance in immune thrombocytopenia.
作者信息
Kapur Rick
机构信息
Sanquin Research, Department of Experimental Immunohematology, Amsterdam and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
出版信息
Cell Mol Immunol. 2022 Jul;19(7):858-860. doi: 10.1038/s41423-022-00880-3. Epub 2022 Jun 15.
Abstract
摘要
相似文献
1
Impaired glucocorticoid receptor expression and mitochondrial metabolism in MDSCs contribute to glucocorticoid resistance in immune thrombocytopenia.骨髓来源的抑制性细胞中糖皮质激素受体表达受损和线粒体代谢异常导致免疫性血小板减少症中的糖皮质激素抵抗。
Cell Mol Immunol. 2022 Jul;19(7):858-860. doi: 10.1038/s41423-022-00880-3. Epub 2022 Jun 15.
2
Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia.糖皮质激素受体通过免疫性血小板减少症中的线粒体代谢调节髓系来源的抑制性细胞功能。
Cell Mol Immunol. 2022 Jul;19(7):764-776. doi: 10.1038/s41423-022-00859-0. Epub 2022 Apr 12.
3
Dexamethasone-Induced Myeloid-Derived Suppressor Cells Prolong Allo Cardiac Graft Survival through iNOS- and Glucocorticoid Receptor-Dependent Mechanism.地塞米松诱导的髓源性抑制细胞通过 iNOS 和糖皮质激素受体依赖的机制延长同种异体心脏移植物的存活。
Front Immunol. 2018 Feb 15;9:282. doi: 10.3389/fimmu.2018.00282. eCollection 2018.
4
Distinct alterations of CD68CD163 M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment.大剂量地塞米松治疗后初诊原发性免疫性血小板减少症患者伴或不伴有完全反应者中 CD68CD163 M2 样巨噬细胞和髓系来源抑制细胞的明显改变。
J Transl Med. 2018 Mar 2;16(1):48. doi: 10.1186/s12967-018-1424-8.
5
Platelet to Lymphocyte Ratio and Glucocorticoid Resistance in Newly Diagnosed Primary Immune Thrombocytopenia: A Retrospective Cohort Study.血小板与淋巴细胞比值与新诊断的原发性免疫性血小板减少症的糖皮质激素抵抗：一项回顾性队列研究。
Med Sci Monit. 2019 Sep 29;25:7321-7331. doi: 10.12659/MSM.916907.
6
Glucocorticoid receptor promotes the function of myeloid-derived suppressor cells by suppressing HIF1α-dependent glycolysis.糖皮质激素受体通过抑制 HIF1α 依赖性糖酵解来促进髓源抑制细胞的功能。
Cell Mol Immunol. 2018 Jun;15(6):618-629. doi: 10.1038/cmi.2017.5. Epub 2017 Mar 13.
7
Glucocorticoid Resistance.糖皮质激素抵抗
Exp Suppl. 2019;111:85-102. doi: 10.1007/978-3-030-25905-1_6.
8
Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance.探索糖皮质激素受体作用从敏感到耐药的分子机制。
Endocr Dev. 2013;24:41-56. doi: 10.1159/000342502. Epub 2013 Feb 1.
9
Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP).糖皮质激素治疗对免疫性血小板减少症（ITP）患者 BAFF 和 APRIL 表达的影响。
Clin Immunol. 2018 Mar;188:74-80. doi: 10.1016/j.clim.2017.12.010. Epub 2017 Dec 26.
10
Platelet-derived TGF-β1 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia.血小板衍生的 TGF-β1 诱导免疫性血小板减少症中髓系来源抑制细胞的功能重编程。
Blood. 2024 Jul 4;144(1):99-112. doi: 10.1182/blood.2023022738.
本文引用的文献
1
Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia.糖皮质激素受体通过免疫性血小板减少症中的线粒体代谢调节髓系来源的抑制性细胞功能。
Cell Mol Immunol. 2022 Jul;19(7):764-776. doi: 10.1038/s41423-022-00859-0. Epub 2022 Apr 12.
2
Potential Diagnostic Approaches for Prediction of Therapeutic Responses in Immune Thrombocytopenia.免疫性血小板减少症治疗反应预测的潜在诊断方法
J Clin Med. 2021 Jul 30;10(15):3403. doi: 10.3390/jcm10153403.
3
Glucocorticoid treatment in patients with newly diagnosed immune thrombocytopenia switches CD14 CD16 intermediate monocytes from a pro-inflammatory to an anti-inflammatory phenotype.糖皮质激素治疗新诊断的免疫性血小板减少症患者可使 CD14 CD16 中间型单核细胞从促炎表型转变为抗炎表型。
Br J Haematol. 2021 Jan;192(2):375-384. doi: 10.1111/bjh.17205. Epub 2020 Dec 18.
4
An update on the pathophysiology of immune thrombocytopenia.免疫性血小板减少症的病理生理学研究进展。
Curr Opin Hematol. 2020 Nov;27(6):423-429. doi: 10.1097/MOH.0000000000000612.
5
American Society of Hematology 2019 guidelines for immune thrombocytopenia.美国血液学会 2019 年免疫性血小板减少症治疗指南。
Blood Adv. 2019 Dec 10;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966.
6
Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.识别和治疗难治性 ITP：诊断困难和联合治疗的作用。
Blood. 2020 Feb 13;135(7):472-490. doi: 10.1182/blood.2019003599.
7
The abnormal function of CD39 regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia.大剂量地塞米松可纠正原发免疫性血小板减少症患者调节性 T 细胞的异常功能。
Ann Hematol. 2019 Aug;98(8):1845-1854. doi: 10.1007/s00277-019-03716-9. Epub 2019 Jun 1.
8
Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).促血小板生成素受体激动剂（TPO-RA）治疗可提高免疫性血小板减少症（ITP）小鼠的血小板计数并降低抗血小板抗体水平。
Platelets. 2020;31(3):399-402. doi: 10.1080/09537104.2019.1624709. Epub 2019 May 30.
9
Antiplatelet antibody-induced thrombocytopenia does not correlate with megakaryocyte abnormalities in murine immune thrombocytopenia.抗血小板抗体诱导的血小板减少症与小鼠免疫性血小板减少症中的巨核细胞异常无关。
Scand J Immunol. 2018 Jul;88(1):e12678. doi: 10.1111/sji.12678.
10
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP).免疫性血小板减少症（ITP）的发病机制与治疗机制
J Clin Med. 2017 Feb 9;6(2):16. doi: 10.3390/jcm6020016.
Zotero 插件